Soichi Sano1, Kosei Oshima2, Ying Wang1, Yasufumi Katanasaka3, Miho Sano2, Kenneth Walsh4. 1. From the Hematovascular Biology Center, Robert M. Berne Cardiovascular Research Center, University of Virginia School of Medicine, Charlottesville (S.S., Y.W., K.W.). 2. Molecular Cardiology, Whitaker Cardiovascular Institute, Boston University School of Medicine, MA (K.O., M.S.). 3. Division of Molecular Medicine, Graduate School of Pharmaceutical Sciences, University of Shizuoka, Yada, Japan (Y.K.). 4. From the Hematovascular Biology Center, Robert M. Berne Cardiovascular Research Center, University of Virginia School of Medicine, Charlottesville (S.S., Y.W., K.W.) kw9ar@virginia.edu.
Abstract
RATIONALE: Clonal hematopoiesis has been associated with increased mortality and cardiovascular disease. This condition can arise from somatic mutations in preleukemic driver genes within hematopoietic stem/progenitor cells. Approximately 40 candidate driver genes have been identified, but mutations in only 1 of these genes, TET2 (ten-eleven translocation-2), has been shown to casually contribute to cardiovascular disease in murine models. OBJECTIVE: To develop a facile system to evaluate the disease characteristics of different clonal hematopoiesis driver genes using lentivirus vector and CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/clustered regularly interspaced short palindromic repeat-associated 9) methodology. Using this methodology, evaluate whether Dnmt3a (DNA [cytosine-5]-methyltransferase 3a)-a commonly occurring clonal hematopoiesis driver gene-causally contributes to cardiovascular disease. METHODS AND RESULTS: Lentivirus vectors were used to deliver Cas9 and guide RNA to introduce inactivating mutations in Tet2 and Dnmt3a in lineage-negative bone marrow cells. After implantation into lethally irradiated mice, these cells were engrafted and gave rise to labeled blood cell progeny. When challenged with an infusion of Ang II (angiotensin II), mice with inactivating mutations in Tet2 or Dnmt3a displayed greater cardiac hypertrophy, diminished cardiac function, and greater cardiac and renal fibrosis. In comparison with Tet2, inactivation of Dnmt3a did not lead to detectable expansion of the mutant hematopoietic cells during the time course of these experiments. Tet2 inactivation promoted the expression of IL (interleukin) 1β, IL-6, and Ccl5, whereas Dnmt3a inactivation promoted the expression of Cxcl1 (CXC chemokine ligand), Cxcl2, IL-6, and Ccl5 in a lipopolysaccharide-stimulated macrophage cell line. CONCLUSIONS: Experiments using lentivirus vector/CRISPR methodology provided evidence suggesting that inactivating DNMT3A mutations in hematopoietic cells contributes to cardiovascular disease. Comparative analyses showed that inactivation of Tet2 and Dnmt3 was similar in their ability to promote Ang II-induced cardiac dysfunction and renal fibrosis in mice. However, gene-specific actions were indicated by differences in kinetics of hematopoietic stem/progenitor cell expansion and different patterns of inflammatory gene expression.
RATIONALE: Clonal hematopoiesis has been associated with increased mortality and cardiovascular disease. This condition can arise from somatic mutations in preleukemic driver genes within hematopoietic stem/progenitor cells. Approximately 40 candidate driver genes have been identified, but mutations in only 1 of these genes, TET2 (ten-eleven translocation-2), has been shown to casually contribute to cardiovascular disease in murine models. OBJECTIVE: To develop a facile system to evaluate the disease characteristics of different clonal hematopoiesis driver genes using lentivirus vector and CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/clustered regularly interspaced short palindromic repeat-associated 9) methodology. Using this methodology, evaluate whether Dnmt3a (DNA [cytosine-5]-methyltransferase 3a)-a commonly occurring clonal hematopoiesis driver gene-causally contributes to cardiovascular disease. METHODS AND RESULTS: Lentivirus vectors were used to deliver Cas9 and guide RNA to introduce inactivating mutations in Tet2 and Dnmt3a in lineage-negative bone marrow cells. After implantation into lethally irradiated mice, these cells were engrafted and gave rise to labeled blood cell progeny. When challenged with an infusion of Ang II (angiotensin II), mice with inactivating mutations in Tet2 or Dnmt3a displayed greater cardiac hypertrophy, diminished cardiac function, and greater cardiac and renal fibrosis. In comparison with Tet2, inactivation of Dnmt3a did not lead to detectable expansion of the mutant hematopoietic cells during the time course of these experiments. Tet2 inactivation promoted the expression of IL (interleukin) 1β, IL-6, and Ccl5, whereas Dnmt3a inactivation promoted the expression of Cxcl1 (CXC chemokine ligand), Cxcl2, IL-6, and Ccl5 in a lipopolysaccharide-stimulated macrophage cell line. CONCLUSIONS: Experiments using lentivirus vector/CRISPR methodology provided evidence suggesting that inactivating DNMT3A mutations in hematopoietic cells contributes to cardiovascular disease. Comparative analyses showed that inactivation of Tet2 and Dnmt3 was similar in their ability to promote Ang II-induced cardiac dysfunction and renal fibrosis in mice. However, gene-specific actions were indicated by differences in kinetics of hematopoietic stem/progenitor cell expansion and different patterns of inflammatory gene expression.
Authors: David P Steensma; Rafael Bejar; Siddhartha Jaiswal; R Coleman Lindsley; Mikkael A Sekeres; Robert P Hasserjian; Benjamin L Ebert Journal: Blood Date: 2015-04-30 Impact factor: 22.113
Authors: José J Fuster; Susan MacLauchlan; María A Zuriaga; Maya N Polackal; Allison C Ostriker; Raja Chakraborty; Chia-Ling Wu; Soichi Sano; Sujatha Muralidharan; Cristina Rius; Jacqueline Vuong; Sophia Jacob; Varsha Muralidhar; Avril A B Robertson; Matthew A Cooper; Vicente Andrés; Karen K Hirschi; Kathleen A Martin; Kenneth Walsh Journal: Science Date: 2017-01-19 Impact factor: 47.728
Authors: Giulio Genovese; Anna K Kähler; Robert E Handsaker; Johan Lindberg; Samuel A Rose; Samuel F Bakhoum; Kimberly Chambert; Eran Mick; Benjamin M Neale; Menachem Fromer; Shaun M Purcell; Oscar Svantesson; Mikael Landén; Martin Höglund; Sören Lehmann; Stacey B Gabriel; Jennifer L Moran; Eric S Lander; Patrick F Sullivan; Pamela Sklar; Henrik Grönberg; Christina M Hultman; Steven A McCarroll Journal: N Engl J Med Date: 2014-11-26 Impact factor: 91.245
Authors: Cristina Leoni; Sara Montagner; Andrea Rinaldi; Francesco Bertoni; Sara Polletti; Chiara Balestrieri; Silvia Monticelli Journal: Proc Natl Acad Sci U S A Date: 2017-02-06 Impact factor: 11.205
Authors: Dirk Heckl; Monika S Kowalczyk; David Yudovich; Roger Belizaire; Rishi V Puram; Marie E McConkey; Anne Thielke; Jon C Aster; Aviv Regev; Benjamin L Ebert Journal: Nat Biotechnol Date: 2014-06-22 Impact factor: 54.908
Authors: Soichi Sano; Kosei Oshima; Ying Wang; Susan MacLauchlan; Yasufumi Katanasaka; Miho Sano; María A Zuriaga; Minoru Yoshiyama; David Goukassian; Matthew A Cooper; José J Fuster; Kenneth Walsh Journal: J Am Coll Cardiol Date: 2018-02-27 Impact factor: 24.094
Authors: Haobo Li; Margaret H Hastings; James Rhee; Lena E Trager; Jason D Roh; Anthony Rosenzweig Journal: Circ Res Date: 2020-02-13 Impact factor: 17.367
Authors: Alexander G Bick; James P Pirruccello; Gabriel K Griffin; Namrata Gupta; Stacey Gabriel; Danish Saleheen; Peter Libby; Sekar Kathiresan; Pradeep Natarajan Journal: Circulation Date: 2019-11-11 Impact factor: 29.690
Authors: Tatyana Kuznetsova; Koen H M Prange; Christopher K Glass; Menno P J de Winther Journal: Nat Rev Cardiol Date: 2019-10-02 Impact factor: 32.419
Authors: Lena Dorsheimer; Birgit Assmus; Tina Rasper; Christina A Ortmann; Khalil Abou-El-Ardat; Katharina C Kiefer; Jedrzej Hoffmann; Florian Seeger; Halvard Bonig; Stefanie Dimmeler; Andreas M Zeiher; Michael A Rieger Journal: Haematologica Date: 2019-11-07 Impact factor: 9.941
Authors: Peter Libby; Robert Sidlow; Amy E Lin; Dipti Gupta; Lee W Jones; Javid Moslehi; Andreas Zeiher; Siddhartha Jaiswal; Christian Schulz; Ron Blankstein; Kelly L Bolton; David Steensma; Ross L Levine; Benjamin L Ebert Journal: J Am Coll Cardiol Date: 2019-07-30 Impact factor: 24.094
Authors: François Potus; Michael W Pauciulo; Elina K Cook; Na Zhu; Alexander Hsieh; Carrie L Welch; Yufeng Shen; Lian Tian; Patricia Lima; Jeffrey Mewburn; Christine L D'Arsigny; Katie A Lutz; Anna W Coleman; Rachel Damico; Brooke Snetsinger; Ashley Y Martin; Paul M Hassoun; William C Nichols; Wendy K Chung; Michael J Rauh; Stephen L Archer Journal: Circulation Date: 2020-03-20 Impact factor: 29.690